Reply to C. Cremolini et al
暂无分享,去创建一个
S. Tejpar | B. Claes | B. Biesmans | H. Piessevaux | B. Jacobs | W. Roock | J. Schutter
[1] B. Vincenzi,et al. Predictors of benefit in colorectal cancer treated with cetuximab: are we getting "Lost in TranslationAL"? , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] J. Vandesompele,et al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] P. Laurent-Puig,et al. KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Manuel Hidalgo,et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.